A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation
Cyclin-dependent kinase 12 (CDK12) is an attractive therapeutic target due to its critical role in transcriptional regulation and DNA damage response and is frequently co-amplified with ERBB2 (HER2) in breast cancer. CDK12 forms an active complex with its obligate partner cyclin K (CCNK), and pharmacological degradation of CCNK has emerged as a promising strategy for disrupting CDK12-dependent transcriptional programs. However, the broad expression and essential functions of the CDK12/CCNK complex may limit the therapeutic window of highly potent molecular glue degraders. Here, we investigate whether antibody-mediated delivery can impart cellular selectivity to a molecular glue degrader through targeting the HER2 receptor. Molecular glues lack the modular architecture of PROTACs, thus linker placement can be the central design problem. We designed SAS1001, a CCNK molecular glue degrader with a solvent-exposed piperazine primed for linker attachment. SAS1001 induced potent and ubiquitin-proteasome system-dependent degradation of CCNK and inhibited proliferation in a range of breast cancer cells. Conjugation to trastuzumab (Tz) generated the HER2-targeted degrader-antibody conjugate Tz-SS2009, which internalized preferentially in HER2-positive cells and produced enhanced CCNK degradation and antiproliferative effects, relative both to HER2-negative cells and to an isotype-matched non-targeting conjugate. Whole proteome analysis further demonstrated CCNK depletion and revealed downstream changes consistent with established roles of the CDK12/CCNK complex in transcriptional regulation. These findings demonstrate that antibody-mediated delivery can redistribute the cellular activity of a potent molecular glue degrader towards antigen-positive cells. In the CR8/DS18 purine series, substitution at a solvent-exposed position preserved CCNK degradation when the degrader was delivered on a full-length IgG. More broadly, this work extends antibody-directed degradation beyond the CRBN-based glues that have dominated the field and illustrates how structural characterization of a glue scaffold can identify a linker attachment point that does not compromise activity.
Authors
- Edward W. Tate (ORCID: https://orcid.org/0000-0003-2213-5814)
- Josephine B. Walton (ORCID: https://orcid.org/0009-0006-5509-9329)
- Paul W. Hogg (ORCID: https://orcid.org/0009-0009-4255-3870)
- Janine L. Gray (ORCID: https://orcid.org/0000-0001-8679-2499)
- Pauline Franz (ORCID: https://orcid.org/0000-0002-2867-0474)
- Zuzanna Kozicka (ORCID: https://orcid.org/0000-0003-0085-6565)
- Léa N. C. Rochet (ORCID: https://orcid.org/0009-0003-5594-6290)
- Nicolas Veillard (ORCID: https://orcid.org/0009-0002-7536-2519)
- Jack W. Houghton (ORCID: https://orcid.org/0000-0002-2971-0271)
- Alina Chrzastek (ORCID: https://orcid.org/0000-0003-1419-0311)
- Aidan B. Pidd
- Damjan Lalović (ORCID: https://orcid.org/0009-0007-0713-3518)
- Jianan Lu
- Sofia Srdanovic (ORCID: https://orcid.org/0009-0004-7266-9384)
- Vanessa Stöcker (ORCID: https://orcid.org/0009-0005-6134-0716)
- Laura C. Helbling (ORCID: https://orcid.org/0009-0006-9851-6890)
- Amy McIntosh
- Thomas Mills
Institutions
- Adc Therapeutics (Switzerland) (CH)
- Imperial College London (GB)
- École Polytechnique Fédérale de Lausanne (CH)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-13
- DOI
- https://doi.org/10.64898/2026.11.12.760175
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- preprint
Funders
- Cancer Research UK
- European Commission
- Engineering and Physical Sciences Research Council